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HB Vaccine in Japan 
     In Japan, there are three companies which concern themselves in the development 
of HB Vaccine. Regarding the Vaccines developed by Kitasato Institute and Green Cross 
co., the licence was given by Ministry of Health and Welfare. After the safety test using 
Chimpanzees, these two HB Vaccines are going to be on the market and available around 
the end of 1985. The HB Vaccine developed by Kaketsuken Institute is now asking for 
the licence of it. Each Vaccine produced by three companies is made from e-Antigen 
negative Plasma, and it was inactivated by formaline after 10 hrs' heat. sterilization at 60 
degrees. The subtype of HBs Antigen of source plasma is adr, and 40µg of HBs Antigen 
is contained in 1ml of HB Vaccine. One dose of each Vaccine is 0.5ml for adult and 0.25 
ml for babies and administrated subcutaneously. The producing method and Alminum 
content as an adjunct are different in these 3 Vaccines. (Table 1) The positive ratio of 
anti HBs reaches maximum point after 3rd vaccination, and the mean titer of anti HBs
Table 1 HB Vaccine in Japan
company I Kitasato Inst. (Green Crossco.IKaketsuken inst. 
purification Ultracentrifuge Absorb Ion exchange 
          KBr colloidal silicate chromatography 
         CsCI 
         Sucrose Ultracentrifuge Ultracentrifuge 
                        CsCI Sucrose
Al. content 300MJ/ml 500/ug/ml 200/ug/ml 
material e Antigen negative sera 
inactivation 60°C 10hrs Formalin treatment 1/2000 37°C 96hrs 
subtype ad (r) 
HBsAntigen 40A19/ml 
1 dose 0.5 ml (20)u9)
increases rapidly at that time, by those phase 3 study. In about 3 years observation of 
acquired anti HBs, anti HBs disappeared in a few cases, in almost all cases, anti HBs 
remains positive but the titer of anti HBs decreases with time. By these results, it is 
said that acquired anti HBs by the use of HB Vaccine remains positive for more than 3 
years. HBV infection in adult is transient, and maternal infant transmission is persistent 
and infected babies become HBV carriers, so the main part of the prevention of HBV 
infection is in the prevention against maternal infant transmission. 
Prevention for the maternal infant transmission of HBV 
     There are many reports for the prevention of maternal infant transmission of HBV, 
and the efficacy is clear. It is reported that the maternal infant transmission occurs only 
in the eAg positive mothers' deliveries in Japan. And the prevention was started 8 years 
ago. At the beginning, it was prevented only passive immunization with HB immunoglo-
blin, and in these 4 years, it is prevented by combination of passive and active immuni-
Fig. 1 Schedules lof the prevention for HBV vertical transmission
zation. It is supposed that more than 10,000 babies born to eAg positive mothers were 
treated by passive or passive active immunization in Japan. We have treated 1,102 babies 
born to eAg positive mothers. Preventive efficacy is 94.3% in all cases. Of those, 569 ba-
bies are observed more than 12 months of age. Preventive efficacy is also 93.1%. We 
have tried 4 different schedules of prevention to those babies. (Fig. 1) In each preventive 
schedule, lml of HB immunogloblin is given to babies as early as possible within 24 hrs after 
birth and same dose of HBIG is given 3 months of age. In schedule A, with some ad-
ditional shots of HBIG, babies were treated only by passive immunization by the use of 
HB immunogloblin. Babies were kept positive to anti HBs at least for one year. Schedule 
B, C and D are the combined treatment with HB immunogloblin and HB Vaccine. In 
addition to passive immunization, in schedule B, C and D, each start of HB Vaccine is 
6 months, 3 months after birth and just after birth. One dose of HB Vaccine contains 10pg 
of HBs antigen. 1,102 babies born to e-Antigen positive mothers have been prevented in 
those schedule. Out of them, 63 babies become carriers, giving the carrier rate is 5.7%. 
(Table 2) In each schedule, the carrier rates are 14.3%, 9.9%, 4.0% and 1.8%. This 
result explains that babies acquire a sufficient amount of anti HBs even by the administ-
ration of HB Vaccine just after birth. Early administration of HB Vaccine prevents to 
development carrier more effectively than the late administration of HB Vaccine.
Table 2. Development to carrier state in each 
          preventive schedule
Group Cases Carrier 
 A 147 21 (14.3) 
 B 91 9 (9.9) 
 C 808 32 (4.0) 
 D 56 1 (1.8) 
Total 1102 63 ( 5.7)
HB Vaccine response in newborns 
     80 babies born to e-Antigen negative mothers were administrated HB Vaccine. HB 
Vaccine is also given 3 times such as just after birth, 1 and 3 months of age. Positive 
rate of anti HBs reaches 86.1% at 4 months of age and 93.6% at 7 months of age. The 
new born babies are getting anti HBs same titer and same positive rate in adult. (Fig. 2) 
     The Ministry of Health and Welfare appropriates about one and half million U. S.
dollars for the prevention of maternal infant transmission of HBV in the budget of 1985 in 
Japan. In this project, all pregnant women will be tested for HBsAg, and if they are 
positive, they will be tested for eAg, the babies born to eAg positive mothers will be 
treated by HBIG and HB Vaccine with public expense. In Japanese national project of 
the prevention against maternal infant transmission of HBV will be started at June, 1984.
                    T 3 T 4 T 7 
cases 80 72 47 
positive cases 43 62 44 
 positive rate (%) 53.8 86.1 93.6 
 average (S/ N) 20.5 66.2 69.0
Fig. 2 Anti-HBs Response and the Titer of Acquired of 
       Anti-HBs in Newborns
Anti viral therapy for chronic hepatitis type B 
     Recently, there is a remarkable progress in the treatment of chronic hepatitis type 
B by the development of anti-DNA viral agent. There are 3 kinds of anti-viral therapy 
such as therapy with interferon, with Ara-A and corticosteroid withdrawal therapy (CWT). 
Compared with CWT and interferon and Ara-A by the level of DNA-Polymerase are the 
marker of HB viral replication, in the duration of administrating interferon and Ara-A, 
the level of DNA-P is reduced and re-elevated after the treatment. On the contrary, 
DNA-P level is elevated with administration of CWT and it decreases after the treatment. 
CWT forms the contrast with the treatment with the use of interferon and Ara-A. In the 
CWT, the host immunity is suppressed by the administration of corticosteroid, then the 
replication of HBV in hepatocytes is accelerated. The immuno-suppression is released by 
the withdrawal of corticosteroid and intense immuno-response to replicated HBV is evoked. 
In this way, HBV is cleared out with the remarkable exacervation of liver function tests.
Out of 37 patients treated with CWT, 21 patients (56.8%) are continuously normal in 
GPT after the therapy. While, out of 74 patients treated Ara-A, 22 patients (29 .7%) are 
continuously normal in GPT. And concerning the continuous negative rate of eAg , it is 
35.1% by CWT and 20.3% by Ara-A. Patient with normal liver function test at least 
more than 6 months after the treatment, which are called "clinical cure" , accounted for 
56.8% in CWT. But out of 74 patients treated with Ara-A with 16g-32g, only 14 .9% 
became continuously negative to eAg, and only 29 .7% showed "clinical cure". In the 
CWT, as well as the treatment interferon and Ara-A more satisfactory result can be ob-
tained if the treatment is given to patients who have high level of transaminases and low 
level of HBV markers such as DNA-P and eAg .
